Novo Nordisk reported quarterly earnings that exceeded expectations, driven by Wegovy pill sales that surpassed forecasts. The company raised its full-year outlook following the strong results.
Wegovy's outperformance directly drove Novo Nordisk's earnings beat and prompted the company to raise its financial guidance, signaling confidence in the drug's commercial trajectory.
No published comments yet.
Quarterly reported positions. These filings can arrive up to 45 days after quarter-end and are not real-time trades.
Institutional ownership: 9.62%
| Owner | Activity | Change | Shares held | Value (thousands) | Reported |
|---|---|---|---|---|---|
| Dodge & Cox | Buy | 1,063,360 (5.5%) | 20,397,110 | $819,760 | 6/30/2026 |
| Loomis Sayles & Co L P | Buy | 1,577,037 (9.267%) | 18,594,352 | $747,307 | 6/30/2026 |
| Franklin Templeton Inc | Sell | -3,042,370 (-18.916%) | 13,041,109 | $524,122 | 6/30/2026 |
Source: Nasdaq
Open short positions reported twice monthly; this is not daily short-sale volume.
Recent reported earnings per share compared with the analyst consensus available from Nasdaq.
| Price T Rowe Associates Inc /Md/ |
| Buy |
| 644,039 (5.823%) |
| 11,704,719 |
| $470,413 |
| 6/30/2026 |
| Morgan Stanley | Buy | 790,669 (7.274%) | 11,659,869 | $468,610 | 6/30/2026 |
| Bank Of America Corp /De/ | Buy | 407,013 (3.779%) | 11,176,712 | $449,192 | 6/30/2026 |
| Capital International Investors | Sell | -2,074,670 (-17.588%) | 9,721,180 | $390,694 | 6/30/2026 |
| Folketrygdfondet | Buy | 441,563 (4.863%) | 9,522,383 | $382,705 | 6/30/2026 |
| Goldman Sachs Group Inc | Buy | 4,059,453 (79.27%) | 9,180,490 | $368,964 | 6/30/2026 |
| Fisher Asset Management, Llc | Sell | -696,155 (-7.717%) | 8,324,948 | $334,580 | 6/30/2026 |
| Arrowstreet Capital, Limited Partnership | Buy | 443,294 (5.663%) | 8,270,785 | $332,403 | 6/30/2026 |
| Everett Harris & Co /Ca/ | Sell | -7,128 (-0.11%) | 6,468,494 | $259,969 | 9/30/2026 |
| Settlement date | Short interest | Avg. daily volume | Change vs. previous report | Days to cover |
|---|---|---|---|---|
| Oct 15, 2026 | 37,436,108 | 12,051,403 | +18.38% | 3.11 |
| Sep 30, 2026 | 31,622,458 | 18,158,493 | +20.06% | 1.74 |
| Sep 15, 2026 | 26,339,706 | 9,017,171 | -16.78% | 2.92 |
| Aug 31, 2026 | 31,648,914 | 11,820,506 | -6.44% | 2.68 |
| Aug 14, 2026 | 33,828,864 | 15,543,902 | +14.97% | 2.18 |
| Jul 31, 2026 | 29,424,036 | 10,177,240 | -5.37% | 2.89 |
| Jul 15, 2026 | 31,094,150 | 9,315,762 | +11.93% | 3.34 |
| Jun 30, 2026 | 27,780,646 | 12,643,545 | +13.49% | 2.20 |
Source: FINRA Consolidated Short Interest
| Fiscal quarter | Reported | EPS | Consensus | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | 0.96 | 0.82 | +17.07% |
| Mar 2026 | May 6, 2026 | 1.04 | 0.87 | +19.54% |
| Dec 2025 | Feb 4, 2026 | 1.00 | 0.9 | +11.11% |
| Sep 2025 | Nov 5, 2025 | 1.02 | 0.77 | +32.47% |
Source: Nasdaq
